{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'maximal achievable reduction in ABR, in which the majority of patients may achieve >75% AT', 'lowering, the therapeutic target. Weight was not a significant covariate in the model, suggesting', 'no advantage to weight-based dosing.', 'The safety of fitusiran has been evaluated in healthy volunteers and patients with moderate to', 'severe hemophilia A and in patients with moderate to severe hemophilia B in the ongoing', 'Phase 1 and Phase 1/2 studies and overall, supports monthly administration of the 80 mg dose in', 'this study. Full details of the safety findings from the Phase 1 and Phase 1/2 studies are', \"presented in the Investigator's Brochure.\", '1.5.', 'Benefit-Risk Assessment', 'Based on the available clinical data (see Section 1.2.2), fitusiran, administered subcutaneously as', 'a once-monthly fixed-dose regimen, may be able to offer potentially reduced bleeding rates for', 'patients receiving factor concentrate or BPA treatment prophylactically or on-demand. Further,', 'the pharmacodynamic profile of fitusiran results in consistent reduction of AT and therefore may', 'provide more consistent increase in thrombin generation and hemostatic protection throughout', 'the dosing interval. The clinical experience to date suggests that in hemophilia A or B patients,', 'with or without inhibitors, fitusiran treatment is associated with reductions in AT, increases in', 'thrombin generation, and reduction of the number of bleeding episodes.', 'Given the mechanism of action of fitusiran, mode of administration, and available safety data,', 'the possible risks associated with the use of fitusiran include thrombosis, liver transaminase', 'abnormalities, and injection site reactions (ISRs). Due to the underlying pro-hemostatic effect of', 'fitusiran, the concomitant treatment of breakthrough bleeding episodes with factor or BPA', 'particularly at doses higher than recommended in the protocol may confer an increased risk of', 'thrombosis. For summary of the completed Phase 1 study, and preliminary interim data from the', 'Phase 1/2 extension study of fitusiran, see Section 1.2.2; further details of fitusiran studies are', \"presented in the Investigator's Brochure.\", 'This clinical protocol has exclusion criteria intended to minimize the risk of thrombosis, liver', 'transaminase abnormalities, and serious ISRs. With respect to the risk of thrombosis, the', 'protocol includes detailed guidance and oversight on treatment of breakthrough bleeding', 'episodes with reduced factor/BPA dosing (Section 6.3.1), and management of operative', 'procedures that occur while patients are on fitusiran (Section 6.6). The protocol also excludes', 'patients with evidence of liver disease (including active viral hepatitis) and stipulates ongoing', 'monitoring for elevated transaminases (Section 6.2.3.1). The safety of trial patients will be', 'overseen by an independent DMC (Section 4.7).', '2.', 'OBJECTIVES', '2.1.', 'Primary Objective', 'To evaluate the efficacy of fitusiran compared to on-demand treatment with BPAs,', 'as determined by the frequency of bleeding episodes.', 'Property of the Sanofi Group - strictly confidential', '33']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '2.2.', 'Secondary Objectives', 'To evaluate the efficacy of fitusiran compared to on-demand treatment with BPAs,', 'as determined by:', 'The frequency of spontaneous bleeding episodes', 'The frequency of joint bleeding episodes', 'Health-related quality of life (HRQOL) in patients >17 years of age', 'To determine the frequency of bleeding episodes during the onset period', 'To determine the safety and tolerability of fitusiran', '2.3.', 'Exploratory Objectives', 'To evaluate the effects of fitusiran as compared to on-demand treatment with BPAs', 'on the following patient-reported outcomes:', 'Patient satisfaction with treatment', 'Patient activity', 'HRQOL in adolescents (12 to <17 years of age)', 'To determine the pharmacodynamic (PD) effect, pharmacokinetics (PK), and', 'immunogenicity of fitusiran', 'To evaluate the effects of fitusiran as compared to on-demand treatment with BPAs', 'on the total weight-adjusted consumption of BPAs', 'To evaluate the effects of fitusiran as compared to on-demand treatment with BPAs', 'on joint status', 'To evaluate the effects of fitusiran as compared to on-demand treatment with BPAs', 'on patient resource use', '3.', 'ENDPOINTS', '3.1.', 'Primary Endpoint', 'Annualized Bleeding Rate (ABR) in the efficacy period', '3.2.', 'Secondary Enppoints', 'ABR in the treatment period', 'Annualized spontaneous bleeding rate in the efficacy period', 'Annualized joint bleeding rate in the efficacy period', 'Change in Haem-A-QOL physical health score and total score in the treatment period', 'ABR in the onset period', 'Property of the Sanofi Group - strictly confidential', '34']\n\n###\n\n", "completion": "END"}